Does TRICARE Cover Prolia (Denosumab)?

What Is Prolia (Denosumab) and Why Does It Require Prior Authorization?

Prolia is a RANK-ligand inhibitor. It binds RANKL, a protein that drives osteoclast formation, and reduces bone resorption. The FREEDOM trial (N=7,868, NEJM 2009) showed denosumab 60 mg every 6 months reduced new vertebral fractures by 68% and hip fractures by 40% over 36 months versus placebo [1]. Because the drug lists at roughly $1,500 per dose and injectable biologics carry a higher formulary tier, TRICARE requires prior authorization to confirm the indication is appropriate before approving coverage [2].

TRICARE follows clinical coverage policies aligned with the Agency for Healthcare Research and Quality evidence reviews and the American Society for Bone and Mineral Research position statements. The 2020 ASBMR task-force statement defined high fracture risk as a T-score at or below -2.5 with one prior fracture, or a T-score at or below -3.0 regardless of fracture history [3]. TRICARE's prior authorization reviewers apply similar thresholds when evaluating Prolia requests.

Denosumab also carries FDA approval for bone loss in cancer patients receiving aromatase inhibitors or androgen deprivation therapy, glucocorticoid-induced osteoporosis, and giant cell tumor of bone. Each indication carries its own coverage pathway under TRICARE [4].

Which TRICARE Plans Cover Prolia?

All active TRICARE plan types include Prolia in their benefit when medical necessity is established. TRICARE Prime, TRICARE Select, TRICARE For Life, TRICARE Reserve Select, and TRICARE Young Adult all use the same Express Scripts formulary and the same prior authorization process [5].

The delivery channel matters for cost. Military treatment facility (MTF) pharmacies dispense Prolia at $0 copay for all plan types. TRICARE Pharmacy Home Delivery (mail order through Express Scripts) charges approximately $46 per fill. Retail network pharmacies charge approximately $60 under TRICARE Prime and approximately $140 under TRICARE Select for a specialty non-preferred drug in this tier [6].

Because Prolia is a biologic administered by injection rather than an oral tablet, it is classified as a specialty drug. Specialty drugs on the TRICARE formulary sit at the highest copay tier for retail dispensing, which is why MTF or mail-order channels produce meaningfully lower out-of-pocket costs [7].

TRICARE Formulary Tier for Prolia (Denosumab)

TRICARE's pharmacy benefit divides drugs into three broad tiers: generic, formulary brand, and non-formulary (which includes most specialty biologics). Prolia sits in the non-formulary specialty tier under the current TRICARE Uniform Formulary [8].

Non-formulary status does not mean excluded. It means:

1. Prior authorization is required before each benefit period.
2. The copay is higher than for formulary brands.
3. The prescriber must document medical necessity.

The Pharmacy and Therapeutics Committee within the Defense Health Agency reviews the Uniform Formulary quarterly. Beneficiaries can check the current status of any drug at the TRICARE formulary search tool at tricare.mil or through the Express Scripts member portal [9].

Prior Authorization Criteria for Prolia Under TRICARE

Prior authorization for Prolia generally requires documentation of four elements. First, a confirmed diagnosis of postmenopausal osteoporosis, male osteoporosis, or another FDA-approved indication such as aromatase-inhibitor-induced bone loss. Second, a recent dual-energy X-ray absorptiometry (DXA) scan showing a T-score at or below -2.5, or clinical evidence of a fragility fracture. Third, documentation that the patient either completed an adequate bisphosphonate trial (typically 12 months of alendronate, risedronate, or zoledronic acid) or has a documented contraindication or intolerance to bisphosphonates. Fourth, ordering by or in consultation with a physician who manages metabolic bone disease [2] [10].

The Endocrine Society's 2019 clinical practice guideline on osteoporosis in postmenopausal women states: "For women at very high risk of fracture, defined as recent fracture especially in the last 12 months, fractures on or after osteoporosis therapy, or very low T-scores (<-3.0), initial treatment with anabolic agents or denosumab may be considered" [11]. TRICARE reviewers may waive the step-therapy requirement when the prescriber cites this guideline language and provides objective risk documentation.

Authorization is typically approved for 12 months, covering two injections, then must be renewed. Renewals require evidence that the patient received the prior injection without serious adverse events and that DXA monitoring is ongoing [12].

Step Therapy Requirements Before Prolia

TRICARE applies step therapy in most Prolia requests for standard-risk postmenopausal osteoporosis. The expected sequence is a minimum 12-month trial of an oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly are the generic first-line agents) before approving the non-formulary specialty biologic [13].

Step therapy exceptions are recognized in specific clinical situations:

• Upper gastrointestinal intolerance, esophageal stricture, or inability to remain upright for 30 minutes after dosing rules out oral bisphosphonates.
• Chronic kidney disease with an estimated glomerular filtration rate (eGFR) <35 mL/min/1.73m2 is a contraindication to bisphosphonates per FDA labeling.
• Osteonecrosis of the jaw or atypical femoral fracture attributed to prior bisphosphonate use.
• Physician documentation of very high fracture risk meeting the ASBMR 2020 criteria, where delaying effective therapy is clinically inappropriate [3].

When any of these exceptions apply, the prescriber should attach the relevant labs, imaging, or gastroenterology notes to the prior authorization form. Express Scripts processes most specialty PA requests within 3 business days, though urgent requests citing imminent fracture risk may be escalated [5].

How Much Does Prolia Cost Under TRICARE?

The list price of Prolia is approximately $1,500 per 60 mg prefilled syringe. With approved prior authorization under TRICARE, the beneficiary cost is dramatically lower depending on where the drug is dispensed [6].

| Dispensing Channel | TRICARE Prime Copay | TRICARE Select Copay | |---|---|---| | Military Treatment Facility | $0 | $0 | | Mail Order (Express Scripts Home Delivery) | ~$46 | ~$46 | | Retail Network Pharmacy | ~$60 | ~$140 | | Retail Non-Network Pharmacy | Cost-share applies | Cost-share applies |

TRICARE For Life beneficiaries have Medicare as primary payer. Medicare Part B covers Prolia as a physician-administered biologic under the buy-and-bill model at 80% of the Medicare allowable after the Part B deductible, with TRICARE For Life covering the remaining 20% in most cases, producing a near-zero out-of-pocket cost [14].

Can You Use the Amgen Prolia Savings Card With TRICARE?

No. Federal law prohibits the use of manufacturer copay assistance cards, patient assistance coupons, or savings cards when a federal health program (including TRICARE, Medicare, and Medicaid) is the primary payer. Accepting such assistance while billing a federal program may constitute a kickback violation under 42 U.S.C. § 1320a-7b(b) [15].

Beneficiaries who cannot afford their copay have three legitimate options. First, use the MTF pharmacy, where the copay is $0. Second, request TRICARE Pharmacy Home Delivery, which carries a lower copay than retail. Third, if TRICARE denies coverage entirely, ask the prescriber whether Amgen's patient assistance program (separate from the commercial savings card) applies, as that program is available to patients without insurance coverage for the drug.

How to Appeal a TRICARE Denial of Prolia

Denials are not final. TRICARE has a structured appeal process with defined timelines [16].

Step 1: Request Reconsideration (within 90 days of denial). The prescriber or beneficiary submits a written reconsideration request to Express Scripts (for pharmacy benefit denials) or to the TRICARE managed care contractor (Humana Military for East/Southeast regions, Health Net Federal Services for West region) for medical benefit denials. A physician reviewer examines the additional clinical documentation.

Step 2: Formal TRICARE Appeal (within 90 days of reconsideration denial). The appeal goes to the TRICARE managed care contractor's appeal unit. This review is conducted by a physician not involved in the initial denial. The contractor must issue a decision within 30 calendar days for standard requests or 72 hours for expedited urgent appeals [17].

Step 3: Independent Review (if still denied). Beneficiaries may request an independent medical review or proceed to a formal hearing. Cases involving more than $300 in dispute may be escalated to a TRICARE Quality Monitoring Contractor review.

Strong appeal packages include: the prescriber's letter of medical necessity citing specific trial data and guideline references, the DXA report with T-scores, fracture history with imaging, documentation of bisphosphonate intolerance or contraindication, and a reference to the FREEDOM trial showing 68% vertebral fracture risk reduction [1]. Denials that fail to account for guideline-supported exceptions are frequently overturned at Step 2.

Prolia vs. Other TRICARE-Covered Osteoporosis Treatments

TRICARE covers several osteoporosis therapies at lower formulary tiers. Understanding the coverage hierarchy helps prescribers build a defensible step-therapy record [18].

Alendronate (generic): Tier 1 generic. No prior authorization. ~$0-$9 copay at retail. First-line per TRICARE formulary.

Risedronate (generic): Tier 1 generic. No prior authorization.

Zoledronic acid 5 mg IV (generic available): Often dispensed under the medical benefit as an infusion. Prior authorization required. Annual dosing is an advantage for adherence.

Raloxifene: Formulary brand for postmenopausal women. Lower copay than Prolia but limited to vertebral fracture prevention; no proven hip fracture benefit [19].

Teriparatide (Forteo) / Abaloparatide (Tymlos): Anabolic agents. Non-formulary specialty tier with PA required. Typically reserved for very high-risk patients or those who have failed antiresorptive therapy [11].

Romosozumab (Evenity): Non-formulary specialty tier with PA required. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced hip fracture risk by 38% versus alendronate alone over 24 months [20].

Prolia occupies a middle position: it is more effective than oral bisphosphonates for hip fracture prevention in head-to-head data and carries a convenient twice-yearly dosing schedule, but it costs more and requires PA. The prescriber's job is to document why the patient cannot use or did not respond to lower-tier agents.

Monitoring and Renewal Considerations for TRICARE Beneficiaries

Denosumab requires sustained dosing. Missing an injection by more than 4 weeks can trigger a rapid rebound in bone turnover markers and increased vertebral fracture risk. A 2017 analysis published in the Journal of Bone and Mineral Research found that discontinuation of denosumab was associated with a mean 7% loss of spine BMD within 12 months and multiple rebound vertebral fractures in some patients [21].

TRICARE's annual PA renewal process creates a potential gap in coverage. Prescribers should submit renewal prior authorization at least 60 days before the next injection is due. If a renewal is denied and an appeal is in progress, the prescriber can request a bridge authorization or administer the injection at an MTF under a direct-care authorization while the appeal resolves [5].

Calcium (1,000-1 to 200 mg/day) and vitamin D (800-1 to 000 IU/day) supplementation should accompany denosumab therapy per standard guidelines. Hypocalcemia must be corrected before each injection; TRICARE's PA criteria may ask for a recent serum calcium level [22].

Serum creatinine and eGFR monitoring is appropriate before each injection, as severe renal impairment increases hypocalcemia risk. DXA scanning every 2 years is recommended by the National Osteoporosis Foundation to track treatment response [23].

A Practical Decision Framework for Prescribers Navigating TRICARE Coverage

The following four-step framework summarizes the path from initial prescription to approved TRICARE coverage for Prolia.

Step 1: Confirm the indication. Order DXA. Confirm T-score <-2.5 or fragility fracture history. Document the FDA-approved indication explicitly in the chart note.

Step 2: Document bisphosphonate history. Record dates, doses, duration, and reason for discontinuation or contraindication. If eGFR is <35 mL/min/1.73m2, attach the lab report. If GI intolerance is the reason, attach gastroenterology notes or pharmacy dispensing records showing a trial attempt.

Step 3: Submit prior authorization via Express Scripts CoverMyMeds or the TRICARE provider portal. Attach the DXA report, relevant lab results, bisphosphonate history, and a brief letter citing FREEDOM trial data and the applicable ASBMR or Endocrine Society guideline recommendation.

Step 4: Advise the patient to use MTF pharmacy or mail order. This eliminates the retail specialty copay and removes the financial barrier that causes patients to delay pickup.

If Step 3 produces a denial, proceed directly to the reconsideration process with additional clinical documentation. Most moderate-risk denials that include complete bisphosphonate intolerance documentation are overturned without reaching a formal appeal [16].

Prolia Safety Profile Relevant to TRICARE Coverage Decisions

TRICARE reviewers occasionally cite safety concerns as grounds for non-coverage in unusual cases. Knowing the safety data allows prescribers to respond accurately [24].

In the FREEDOM trial, the most common adverse events were back pain (34.7% denosumab vs. 35.4% placebo), arthralgia (21.3% vs. 19.0%), and nasopharyngitis (26.7% vs. 25.6%), none of which were significantly different from placebo rates [1]. Serious infections occurred in 4.1% of the denosumab group versus 3.4% placebo over 36 months, a difference that was not statistically significant at P = 0.12.

Osteonecrosis of the jaw (ONJ) occurred in 13 subjects across the long-term FREEDOM extension (N=4,550 patient-years of follow-up), an incidence of roughly 0.3% per year in that extended cohort [25]. Atypical femoral fractures have been reported with denosumab but at lower frequency than with long-term bisphosphonate use, based on post-marketing surveillance data compiled by the FDA [4].

Prescribers should document that they have reviewed contraindications (uncorrected hypocalcemia) and relative risks (invasive dental procedures, severe immunosuppression) with the patient. This documentation strengthens both the clinical record and any PA submission.